Liège, Belgium – 04 December 2023 – 7AM CET – Regulated information – inside information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing ...
Product previously referenced as HY-016, targeting genital and perianal warts US Commercialization by partner Padagis to start in December 2023 Second U.S. market approval of the year after Maxigesic® ...
Product previously referenced as HY-016, targeting genital and perianal warts US Commercialization by partner Padagis to start in December 2023 Second U.S. market approval of the year after Maxigesic® ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback